Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Palo Alto Networks Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Palo Alto Networks Inc trades at $318.05 (market cap $274.69B). The key difference: Palo Alto Networks Inc is far larger — about 61.2× ACADIA Pharmaceuticals Inc.'s market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | PANW | |
|---|---|---|
Market Cap | $4.49B | $274.69B |
Sector | Health | Technology |
52-Week High | $28.06 | $357.53 |
52-Week Low | $20.06 | $141.67 |
Enterprise Value | $3.69B | $273.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Palo Alto Networks (PANW) trades at $337.04, down 3.17% today but remains near all-time highs with strong bullish momentum. The stock has surged over 150% from yearly lows, driven by robust cybersecurity demand and AI-driven security solutions. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Revenue growth remains solid at $9.22B for 2025, though valuation multiples appear elevated with a P/E of 310.9 and P/S of 24.82. Technical indicators show mixed signals with moving averages bullish but RSI levels suggesting overbought conditions.
Outlook: PANW benefits from durable growth drivers including platformization and AI cybersecurity adoption, with analysts projecting a 19-23% upside to consensus targets. Risks include premium valuation sensitivity, integration costs from acquisitions, and competitive pressures. The stock's trajectory hinges on execution of its $20B NGS ARR target by 2030 and maintaining industry leadership amid rising AI threats. Near-term support lies at $324, with resistance at $371.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
